Clinical trials: Koch's Disease
Mycobacterium Tuberculosis, LTBI (Latent TB Infection)
The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian Population
About 2 billion people worldwide are infected with tuberculosis (TB). Ninety percent of those people have latent TB infection (LTBI).
- Conditions
- Mycobacterium Tuberculosis, LTBI (Latent TB Infection), Malnutrition, Diabetes Mellitus
- Trial name
- NCT04526613
- Where
- India
- Volunteers
- 626 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis Infection
Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)
Dose comparison study of tuberculin purified protein derivative (PPD)Aplisol with the standard tuberculin purified derivative (PPD-S2).
- Trial name
- NCT01689831
- Testing
- To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2.
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- JHP Pharmaceuticals LLC
Tuberculosis, TPT
Systems Analysis and Improvement Approach to Prevent TB
This randomized trial uses the evidence-based Systems Analysis and Improvement Approach (SAIA) adapted for tuberculosis (SAIA-TB) to assess the comprehensive tuberculosis (TB) care cascade across 16 clinics in rural Eastern Cape…
- Conditions
- Tuberculosis, TPT, TB - Tuberculosis
- Trial name
- SAIA-TB (NCT06314386)
- Testing
- Systems Analysis and Improvement Approach for TB (SAIA-TB)
- Where
- 16 sites in South Africa
- Volunteers
- 19,560 people
- Sponsor
- Boston College
Tuberculosis, HIV
TMC207-TiDP13-C110: Interaction Study With Lopinavir/Ritonavir in Healthy Volunteer
The purpose of this Phase I, open-label, randomized crossover trial is to investigate the pharmacokinetic interaction between steady-state lopinavir/ritonavir and single-dose TMC207 in healthy volunteers.
- Trial name
- NCT00828529
- Testing
- TMC207
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Latent Tuberculosis
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care…
- Trial name
- ASTERoiD (NCT03474029)
- Testing
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 3,400 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, Tuberculosis
A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients
This is a randomized, open-label study comparing three existing treatment strategies of ART initiation in HIV/TB co-infected patients: Group 1: early initiation of ART with TB treatment, Group 2: initiation of ART upon completion…
- Trial name
- SAPIT (NCT00398996)
- Testing
- Early versus intermediate versus late initiation of ART
- Where
- South Africa
- Volunteers
- 642 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
Hay Fever, Asthma
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios.
- Conditions
- Hay Fever, Asthma, Acute Upper Respiratory Infection, Pulmonary Embolism
- Trial name
- EPLLMMRDC (NCT06457269)
- Testing
- Diagnosis by three human doctors, Diagnosis by ChatGPT-3.5 (with search capabilities), Diagnosis by ChatGPT-3.5 (without search capabilities)
- Where
- China
- Volunteers
- 703 people
- Sponsor
- North Sichuan Medical College
Tuberculosis, Pulmonary
Evaluation of CRISPR-based Test for the Rapid Identification of TB in Pulmonary Tuberculosis Suspects
This observational Mycobacterium tuberculosis (MTB) diagnostics evaluation study is a prospective study of pulmonary TB suspects who are undergoing sputum or bronchoalveolar lavage fluid (BALF) evaluation for pulmonary TB.
- Trial name
- NCT04074369
- Testing
- CRISPR-based Test
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Huashan Hospital
Tuberculosis
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
This is a Phase I, single-center, double-blinded, randomized, placebo-controlled, five-period cross-over clinical study of PA-824 to evaluate the effect of PA-824 and of PA-824 plus moxifloxacin on cardiac repolarization (QT/QTc…
- Trial name
- NCT01674218
- Testing
- Moxifloxacin, PA-824
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multi Drug Resistant Tuberculosis, HIV Infections
An Adaptive Randomized Controlled Trial
This is a prospective, adaptive, randomized controlled trial comparing the effectiveness of 4 intervention arms on a combined endpoint in adults with confirmed MDR-TB HIV initiating Bedaquiline-containing MDR-TB treatment…
- Trial name
- ADAP-TIV (NCT05633056)
- Testing
- Adherence support intevention
- Where
- South Africa
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Columbia University
Tuberculosis, Pulmonary
TuBerculosis Viability Interregional Study and Agreement on Biological Tests
The objective of the present study is to confirm in a multicentric study the utility of our viability test in large cohort of smear-positive pulmonary tuberculosis patients under treatment and to determine if the test could help…
- Trial name
- TBVISA (NCT04968886)
- Testing
- Diagnostic Test: viability test on sputum and comparision with culture results (reference test)
- Where
- France
- Volunteers
- 125 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
TUBERCULOSIS
Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis
Methodology This is a single-center study carried out as part of routine patient care. The aim of the study is to determine the performance of the 2nd generation TB-IGRA test in the diagnosis of tuberculosis.
- Trial name
- TUBIGRA (NCT06485895)
- Testing
- test IGRA, TEST QUATIFERON TB Gold Plus
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Tuberculosis, Pulmonary
Digital Health Intervention to Improve TPT Uptake
Despite the evidence of the prevention and control measures of tuberculosis (TB), it still has an impact on the health, social, and economic aspects of the population.
- Trial name
- DHiTPT (NCT07313995)
- Testing
- Digital health intervention
- Where
- 14 sites in Ethiopia
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Arba Minch University
Tuberculosis, Diabetes Mellitus
Immunobiology of Diabetes and Tuberculosis
The study hypothesis is that type 2 diabetics have abnormal cell-mediated immunity to tuberculosis manifesting as altered cytokine responses by peripheral blood mononuclear cells (PBMCs).
- Trial name
- NCT00568854
- Testing
- BCG
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Stanford University
Tuberculosis, Diagnostic Techniques and Procedures
Histopathological Techniques and PCR on Tissues Included in Paraffin for the Diagnosis of Tuberculosis
Tuberculosis (TB) remains a major public health problem nowadays. About 30% of the world population is infected with Mycobacterium tuberculosis.
- Conditions
- Tuberculosis, Diagnostic Techniques and Procedures, Sensitivity and Specificity, Polymerase Chain Reaction
- Trial name
- NCT02978131
- Testing
- Histopathological study, Molecular study (Polymerase chain reaction)
- Volunteers
- 20 people
- Sponsor
- Lille Catholic University
Tuberculosis
A Home-Based Approach to Tuberculosis Preventive Treatment Management
Background: Tuberculosis (TB), though preventable and curable, remains a major public health concern worldwide. While elimination of tuberculosis infection (TBI) is critical to TB elimination, TBI continues to represent a…
- Trial name
- NCT07479030
- Testing
- A home-based approach to TB preventive treatment management
- Where
- Ethiopia
- Volunteers
- 1,300 people
- Sponsor
- Dilla University
Tuberculosis, HIV
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
This will be a Phase IIIb Clinical Trial, an international multicenter, randomized, three-arm, non-comparative trial of efficacy, safety, and tolerability of the dual therapy regimen dolutegravir plus lamivudine either twice…
- Trial name
- DOVETAIL (NCT06497465)
- Testing
- Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
- Where
- 5 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pleural Effusion
Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion
Tubercular pleural effusion is the second most common form of extrapulmonary tuberculosis (EPTB) seen in clinical practice after tuberculosis (TB) lymphadenitis.
- Trial name
- NCT01560078
- Where
- India
- Volunteers
- 360 people
- Sponsor
- All India Institute of Medical Sciences
Tuberculosis
Innovative Approaches to Tuberculosis Control
This study is designed as a cluster-randomized trial. The cluster unit is at the community level. Communities will be randomized to 1 of 2 study arms: DOTS+ACF or DOTS.
- Trial name
- NCT00472316
- Testing
- Active Case Finding for Tuberculosis
- Where
- Brazil
- Volunteers
- 1,000 people
- Sponsor
- Johns Hopkins University
Tuberculosis Infection
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died because of it, despite the…
- Trial name
- TUBILI (NCT06539455)
- Testing
- standard anti-TB treatment
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Stefania Cheli
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.